Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1995-01-24
2000-08-22
Low, Christopher S. F.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 11, 514 12, 514 13, 514 14, 514 16, 530317, 530326, 530327, 530328, 530330, A61K 3812, C07K 512
Patent
active
061072737
ABSTRACT:
TNF.alpha. antagonist compounds and methods of using the same are disclosed. The compounds comprise a molecular surface that is substantially similar to at least one molecular surface of human TNF.alpha.. The compounds bind to TNF receptors but do not produce the same biological effect as that which occurs when TNF.alpha. binds to a TNF receptor. Methods of inhibiting tumor necrosis factor activity are disclosed. The methods comprise the step of contacting tumor necrosis factor alpha with a TNF.alpha. antagonist. Methods of treating individuals suspected of suffering from or being susceptible to a disease or disorder mediated by tumor necrosis factor-alpha activity are disclosed. The methods comprise the step of administering to said individual a therapeutically effective amount of a TNF.alpha. antagonist.
REFERENCES:
File Caplus on STN. No. 119:6744. McDonnell et al. ImmunoMethods, vol. 1, No. 1, pp. 33-39. (abstract and registry No.), 1993.
File Caplus on STN. No. 74:23122. Hiskey et al. J. Org. Chem. vol. 36, No. 1, A. (abstract and registry No.), 1971.
File Caplus on STN. No. 117:192349. Bhatnatger et al. WO 92/09625, Jun. 11, 1992. (abstract and registry No.).
Chemical Abstract No. 1992:572120 on STN. Boehm et al. `Preparation of Tumor Necrosis Factor Agonists and Antagonists`, DE-3841761, Jun. 13, 1990, Abstract and Structure Query, 1992.
Bajusz, S. `Significance of D-Amino-Acid Residues in Biologically Active Peptides`, Pharmazie, 34, 5/6 1979.
Rudinger, J `Characteristics of amino acids as components of peptide hormones sequence` in Peptide Hormones, (ed. J.A. Parsons). University Park Press, Baltimore, pp. 1-7, 1976.
Sugihara et al. `Studies on Cyclic Petides. 5. Conformation and Interaction With Small Molecules of Cyclic Hexapeptides Containing Glutamic Acid or Aspartic Acid Residues`, J. Org. Chem. vol. 41, No. 15, pp. 2584-2590. (1976).
Aderka et al., "Stabilization of The Bioactivity of Tumor Necrosis Factor by Its Soluble Receptors", J. Exp. Med. 175: 323-329 (1992).
Beutler, Bruce and Cerami, Anthony, "The Biology of Cachectin/TNF--A Primary Mediator of The Host Response" Ann. Rev. Immunol. 1989 7:625-655.
Camussi et al., "Tumor Necrosis Factor/Cachetin Stimulates Peritoneal Macrophages, Polymorphonuclear Neutrophils, and Vascular Endothelial Cells to Synthesize and Release Platelet-Activating Factor" J. Exp. Med. 166: 1390-1404 (1987).
Carswell, E.A. et al., "An Endotoxin-Induced Serum Factor That Causes Necrosis of Tumors", Proc. Natl. Acad. Sci. USA 72: 3666-3670 (1975).
Cerami, Anthony and Beutler, Bruce, "The role of cachectin/TNF in endotoxic shock and cachexia" Immunol. Today 1988 9, 28-31.
Debets, Joop M.H. et al., "The Role of Tumor Necrosis Factor/Cachectin in Septic Shock", Second Vienna Shock Forum: 463-466 (1989).
Fiers, W., "Tumor Necrosis Factor", Febs Letters 1991 285, 199-212.
Goeddel, D.V. et al., "Tumor Necrosis Factors: Gene Structure and Biological Activities" Cold Spring Harbor Symposia on Quantitative Biology 1986 LI, 597-609.
Kern, K.A. and Norton, J.A., "Cancer Cachexia", J. of Parenteral and Enteral Nutrition 1988, 12(3), 286-298.
Kornbluth, R.S. and Edgington, T.S., "Tumor necrosis factor production by human moncytes is a regulated event: induction of TNF-a-Mediated cellular cytotoxicity by endotoxin", J. of Immunology 1986, 137(8), 2585-2591.
Kriegler, M. et al., A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF, Cell 1988, 53, 45-53.
Merrifield, R.B., "Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide", J. Am. Chem. Soc., 1963, 85, 2149-2154.
Michie, H.R. et al., "Tumour Necrosis Factor and Bacterial Sepsis" Br. J. Surg. 1989 76, 670-671.
Michie, Hamish R., et al., "Detection of Circulating Tumor Necrosis Factor After Endotoxin Administration" New Eng. J. of Med. 1988 318, 1481-1486.
Michie, Hamish R., et al., "Tumor Necrosis Factor and Endotoxin Induce Similar Metabolic Responses in Human Beings" Surgery 1988 104, 280-286.
Michie, Hamish R., et al., "Chronic TNF Infusion Causes Anorexia but Not Accelerated Nitrogen Loss" Ann. Surg. 1989 209, 19-24.
Oliff, A., "The role of tumor necrosis factor (cachectin) in cachexia", Cell 1988, 54, 141-142.
Oliff, A. et al., "Tumors secreting human TNF/cachectin induce cachexia in mice", Cell 1987, 50, 555-563.
Piguet et al., "Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease", J. Exp. Med. 166:1280-1289.
Pober et al., "Activation of cultured human endothelial cells by recombinant lymphotoxin: comparison with tumor necrosis factor and interleukin 1 species", The journal of immunology 138:3319-3324 (1987).
Pober et al., "Two distinct monokines, interleukin 1 and tumor necrosis factor, each independently induce biosynthesis and transient expression of the same antigen on the surface of cultured human vascular endothelial cells.sup.1 ", The Journal of Immunology, 136 (5) :1680-1687 (1986).
Porteu, F. and Nathan, C., "Shedding of tumor necrosis factor receptors by activated human neutrophils", J. Exp. Med., 172:599-607 (1990).
Pujol-Borrell, Ricardo et al., "HLA class II induction in human islet cells by interferon-.gamma. plus tumor necrosis factor or lymphotoxin", nature, 326:304-306 (1987).
Revhaug, Arthur et al., "Inhibition of Cyclo-oxygenase Attenuates the Metabolic Response to Endotoxin in Humans", Arch Surg 1988, 123, 162-170.
Silva, Ayona T. et al., "Prophylactic and Therapeutic Effects of a Monoclonal Antibody to Tumor Necrosis Factor-.alpha. in Experimental Gram-Negative Shock" JID 162: 421-427 (1990).
Simpson, Steven Q. et al., "Role of Tumor Necrosis Factor in Sepsis and Acute Lung Injury", Crit. Care. Clinic 1989 5, 27-47.
Smith, Richard A., et al., "The Active Form of Tumor Necrosis Factor is a Trimer" J. of Biol. Chem. 1987 262 (15) 6951-6954.
Tracey, Kevin J. et al., "Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia", Nature 1987, 330(17), 662-664.
Waage, A. et al., "Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease", The Lancet 1987, Feb. 14.
Williams, Richard O. et al., "Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis", Proc. Natl. Acad. Sci. USA 1992, 89, 9784-9788.
Jameson Bradford A.
Noe Mariadele
Gupta Anish
Low Christopher S. F.
Thomas Jefferson University
LandOfFree
Tumor necrosis factor inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tumor necrosis factor inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tumor necrosis factor inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-581190